Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.

Psychedelics and Psychedelic-Assisted Psychotherapy

Reiff, Collin M., Richman, Elon E., Nemeroff, Charles B., Carpenter, Linda L., Widge, Alik S., Rodriguez, Carolyn I., Kalin, Ned H., McDonald, William M., and the Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research · 2020 · American Journal of Psychiatry

Abstract

Objective: The authors provide an evidenced-based summary of the literature on the clinical application of psychedelic drugs in psychiatric disorders. Methods: Searches of PubMed and PsycINFO via Ovid were conducted for articles in English, in peer-reviewed journals, reporting on “psilocybin,” “lysergic acid diethylamide,” “LSD,” “ayahuasca,” “3,4-methylenedioxymethamphetamine,” and “MDMA,” in human subjects, published between 2007 and July 1, 2019. A total of 1,603 articles were identified and screened. Articles that did not contain the terms “clinical trial,” “therapy,” or “imaging” in the title or abstract were filtered out. The 161 remaining articles were reviewed by two or more authors. The authors identified 14 articles reporting on well-designed clinical trials investigating the efficacy of lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and ayahuasca for the treatment of mood and anxiety disorders, trauma and stress-related disorders, and substance-related and addictive disorders as well as in end-of-life care. Results: The most significant database exists for MDMA and psilocybin, which have been designated by the U.S. Food and Drug Administration (FDA) as “breakthrough therapies” for posttraumatic stress disorder (PTSD) and treatment-resistant depression, respectively. The research on LSD and ayahuasca is observational, but available evidence suggests that these agents may have therapeutic effects in specific psychiatric disorders. Conclusions: Randomized clinical trials support the efficacy of MDMA in the treatment of PTSD and psilocybin in the treatment of depression and cancer-related anxiety. The research to support the use of LSD and ayahuasca in the treatment of psychiatric disorders is preliminary, although promising. Overall, the database is insufficient for FDA approval of any psychedelic compound for routine clinical use in psychiatric disorders at this time, but continued research on the efficacy of psychedelics for the treatment of psychiatric disorders is warranted.

Overview

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2019.19010035

Cites

121 of 121 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 120 references

Research works printed but not linked: 13

  1. Lee M, 1992, Acid Dreams: The Complete History of LSD: The CIA, The Sixties, and Beyond
  2. Darling DC, 2006, Sacred Mushroom of Visions: Teonanácatl: A Sourcebook on the Psilocybin Mushroom
  3. Pahnke WN, 1969, Int Psychiatry Clin, 5, 149
  4. Abramson HA: The Use of LSD in Psychotherapy, in Transactions of a Conference on d-Lysergic Acid Diethylamine (LSD-25). New York: Josiah Macy Jr. Foundation Publications, 1959
  5. Grof S, 1977, The Human Encounter With Death
  6. Labate BC, 2009, Ayahuasca Religions: A Comprehensive Bibliography and Critical Essays
  7. Holland J, 2001, Ecstasy: The Complete Guide
  8. Mithoefer MC, 2013, A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder
  9. Grof S, 2008, LSD Psychotherapy
  10. Kalant H, 2001, CMAJ, 165, 917
  11. Preller KH, 2018, Behavioral Neurobiology of Psychedelic Drugs, 221
  12. Aarde SM, 2017, Neuropharmacology of New Psychoactive Substances (NPS): The Science Behind the Headlines, 145
  13. Heifets BD, JAMA Psychiatry

Cited by

See all 649

Metadata

Authors
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R.
Affiliations
  • Emory University (US)
  • Department of Psychiatry, New York University School of Medicine, New York (Reiff); Department of Psychiatry and Human Behavior, Emory University School of Medicine, Atlanta (Richman, McDonald); Department of Psychiatry, Dell Medical School and the Institute for Early Life Adversity Research, University of Texas at Austin (Nemeroff); Department of Psychiatry and Human Behavior, Butler Hospital, Brown University, Providence, R.I. (Carpenter); Department of Psychiatry and Behavioral Sciences, University of...
Venue
American Journal of Psychiatry
Published
2020-05-01
Volume
177
Issue
5
Pages
391-410
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W3006905788
Cited by
649
References
120
Citations by year
2026: 93 · 2025: 126 · 2024: 129 · 2023: 113 · 2022: 102 · 2021: 60 · 2020: 26
FWCI
5.86
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute on Aging (P30AG059307)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Health › Religion, Spirituality, and Psychology
Keywords
psychedelics, psychedelic-assisted psychotherapy, psilocybin, LSD, ayahuasca, MDMA, post-traumatic stress disorder, treatment-resistant depression, cancer-related anxiety, substance use disorders, trauma and stress-related disorders, end-of-life care
MeSH terms
Mental Disorders, Hallucinogens, Humans, Lysergic Acid Diethylamide, Psilocybin, Psychotherapy, N-Methyl-3,4-methylenedioxyamphetamine, Evidence-Based Practice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Psychedelics and Psychedelic-Assisted Psychotherapy. https://app.cochat.ai/papers/10.1176/appi.ajp.2019.19010035
The paper
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R. (2020). Psychedelics and Psychedelic-Assisted Psychotherapy. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2019.19010035

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.